X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC LTD with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC LTD vs DIVIS LABORATORIES - Comparison Results

ALEMBIC LTD    Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC LTD DIVIS LABORATORIES ALEMBIC LTD/
DIVIS LABORATORIES
 
P/E (TTM) x 50.3 35.4 142.3% View Chart
P/BV x 2.2 6.9 31.3% View Chart
Dividend Yield % 0.5 0.7 72.5%  

Financials

 ALEMBIC LTD   DIVIS LABORATORIES
EQUITY SHARE DATA
    ALEMBIC LTD
Mar-18
DIVIS LABORATORIES
Mar-18
ALEMBIC LTD/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs721,142 6.3%   
Low Rs34533 6.4%   
Sales per share (Unadj.) Rs4.7146.6 3.2%  
Earnings per share (Unadj.) Rs6.133.0 18.5%  
Cash flow per share (Unadj.) Rs6.238.4 16.3%  
Dividends per share (Unadj.) Rs0.2010.00 2.0%  
Dividend yield (eoy) %0.41.2 31.6%  
Book value per share (Unadj.) Rs40.7222.8 18.2%  
Shares outstanding (eoy) m267.03265.47 100.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x11.35.7 197.2%   
Avg P/E ratio x8.725.3 34.2%  
P/CF ratio (eoy) x8.521.8 38.9%  
Price / Book Value ratio x1.33.8 34.7%  
Dividend payout %3.330.3 10.8%   
Avg Mkt Cap Rs m14,139222,318 6.4%   
No. of employees `000NA10.8 0.0%   
Total wages/salary Rs m2074,561 4.5%   
Avg. sales/employee Rs ThNM3,616.0-  
Avg. wages/employee Rs ThNM423.8-  
Avg. net profit/employee Rs ThNM814.9-  
INCOME DATA
Net Sales Rs m1,25538,915 3.2%  
Other income Rs m3701,134 32.6%   
Total revenues Rs m1,62540,049 4.1%   
Gross profit Rs m11112,617 0.9%  
Depreciation Rs m381,425 2.7%   
Interest Rs m213 12.8%   
Profit before tax Rs m44212,313 3.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m243,543 0.7%   
Profit after tax Rs m1,6308,770 18.6%  
Gross profit margin %8.932.4 27.3%  
Effective tax rate %5.428.8 18.8%   
Net profit margin %129.822.5 576.2%  
BALANCE SHEET DATA
Current assets Rs m1,86745,351 4.1%   
Current liabilities Rs m5916,507 9.1%   
Net working cap to sales %101.699.8 101.8%  
Current ratio x3.27.0 45.3%  
Inventory Days Days94127 74.4%  
Debtors Days Days7495 77.3%  
Net fixed assets Rs m1,79121,160 8.5%   
Share capital Rs m534531 100.6%   
"Free" reserves Rs m10,32458,625 17.6%   
Net worth Rs m10,85859,156 18.4%   
Long term debt Rs m410-   
Total assets Rs m11,59167,832 17.1%  
Interest coverage x260.9926.8 28.1%   
Debt to equity ratio x00-  
Sales to assets ratio x0.10.6 18.9%   
Return on assets %14.112.9 108.7%  
Return on equity %15.014.8 101.3%  
Return on capital %15.220.8 72.9%  
Exports to sales %1.50-   
Imports to sales %21.021.8 96.2%   
Exports (fob) Rs m19NA-   
Imports (cif) Rs m2638,485 3.1%   
Fx inflow Rs m1932,359 0.1%   
Fx outflow Rs m2649,042 2.9%   
Net fx Rs m-24423,317 -1.0%   
CASH FLOW
From Operations Rs m2367,759 3.0%  
From Investments Rs m-224-4,783 4.7%  
From Financial Activity Rs m-27-3,142 0.8%  
Net Cashflow Rs m-15-166 8.9%  

Share Holding

Indian Promoters % 64.0 52.0 123.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 11.8 1.7%  
FIIs % 9.7 19.0 51.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 17.2 151.7%  
Shareholders   54,701 31,796 172.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC LTD With:   STRIDES PHARMA SCIENCE  ELDER PHARMA  VENUS REMEDIES  DR. DATSONS LABS  WOCKHARDT LTD.  

Compare ALEMBIC LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 300 Points Lower; Metal and IT Stocks Witness Selling(Closing)

Share markets in India witnessed most of the selling pressure during closing hours and ended their trading session on a negative note.

Related Views on News

ALEMBIC LTD Announces Quarterly Results (2QFY19); Net Profit Up 4.0% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, ALEMBIC LTD has posted a net profit of Rs 294 m (up 4.0% YoY). Sales on the other hand came in at Rs 336 m (up 3.1% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (2QFY19); Net Profit Up 92.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 92.3% YoY). Sales on the other hand came in at Rs 13 bn (up 44.3% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

5G Stocks: Cutting-Edge Technology that Could Make You Very Rich...(Profit Hunter)

Nov 12, 2018

A brand new technology and a stock that could soar with the upcoming 5G rollout.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Investing In Small Cap Funds? Read This Before You Invest(Outside View)

Nov 19, 2018

PersonalFN explains the care to take when investing in small-cap funds and the approach to follow.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC LTD SHARE PRICE


Nov 20, 2018 (Close)

TRACK ALEMBIC LTD

  • Track your investment in ALEMBIC LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC LTD 8-QTR ANALYSIS

COMPARE ALEMBIC LTD WITH

MARKET STATS